Search results for "ALS Unit"

showing 3 items of 3 documents

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

2016

// Francesco Passiglia 1, * , Giuseppe Bronte 1, * , Viviana Bazan 1, * , Clara Natoli 2 , Sergio Rizzo 1 , Antonio Galvano 1 , Angela Listi 1 , Giuseppe Cicero 1 , Christian Rolfo 3 , Daniele Santini 4 , Antonio Russo 1 1 Section of Medical Oncology, Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy 2 Department of Medical, Oral and Biotechnological Sciences, University “G. D’Annunzio”, Chieti, Italy 3 Phase I- Early Clinical Trials Unit, Oncology Department and Multidisciplinary Oncology Center Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium 4 Medical Oncology Department, Campus Biomedico, University of Rome, Rome, Italy * These auth…

0301 basic medicineOncologyPD-L1medicine.medical_specialtyLung NeoplasmsAnti-PD1/PD-L1 MoAbsmedicine.medical_treatmentAnti-PD1/PD-L1 MoAbAntineoplastic AgentsCochrane LibraryNSCLCB7-H1 Antigen03 medical and health sciences0302 clinical medicineCarcinoma Non-Small-Cell LungPD-L1Internal medicineOutcome Assessment Health CareBiomarkers TumorOdds RatioHumansMedicineLung cancerBiologybiologybusiness.industryAntibodies MonoclonalImmunotherapyOdds ratioPrognosismedicine.diseaseAnti-PD1/PD-L1 MoAbs; Immunotherapy; NSCLC; PD-L1; Predictive biomarker; OncologyImmunohistochemistryClinical trialPredictive biomarker030104 developmental biologyClinical trials unitOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisImmunologybiology.proteinHuman medicineImmunotherapybusinessResearch Paper
researchProduct

Early Referral to an ALS Center Reduces Several Months the Diagnostic Delay: A Multicenter-Based Study.

2020

Objective: To analyze those factors contributing to the diagnostic delay in ALS.Methods: Consecutive ALS patients were categorized as those studied in departmental hospitals and those studied in a referral ALS center. Demographic and clinical variables, together with data of the diagnostic pathway were collected. Multivariable models were used to assess their effect in the time between symptoms onset and the first neurologist visit (time symptoms-neurologist), in the time between the first neurologist visit and the diagnosis (time neurologist-diagnosis) and in the diagnostic delay.Results: 166 ALS patients with a median diagnostic delay of 11.53 months (IQR: 6.68, 15.23) were included. The …

Pediatricsmedicine.medical_specialtyamyotrophic lateral sclerosisALS UnitClinical variablesReferrallcsh:RC346-42903 medical and health sciences0302 clinical medicinemental disordersmedicine030212 general & internal medicineAmyotrophic lateral sclerosislcsh:Neurology. Diseases of the nervous systemOriginal Researchdiagnostic timelinesbusiness.industryUpper motor neuronmedicine.diseasediagnostic delaynervous system diseasesdiagnostic pathwaymedicine.anatomical_structureNeurologyReferral centerBulbar onsetProgression rateNeurology (clinical)business030217 neurology & neurosurgeryEarly referralFrontiers in neurology
researchProduct

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A. Okines, M. Verheij, W. Allum, D. Cunningham & A. Cervantes On behalf of the ESMO Guidelines Working Group* GI Clinical Trials Unit, Royal Marsden Hospital, Sutton, UK; Department of Radiation Oncology and Division of Cellular Biochemistry, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgery, Royal Marsden Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton, UK; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

medicine.medical_specialtyPalliative careTreatment outcomeMeta-Analysis as TopicStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsGastroscopyRadiation oncologyEpidemiologymedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicRadiotherapybusiness.industryIncidenceGeneral surgeryPalliative CareCancerHematologymedicine.diseaseCombined Modality TherapySurvival AnalysishumanitiesSurgeryEuropeClinical PracticeTreatment OutcomeOncologyClinical trials unitDiagnosis treatmentChemotherapy AdjuvantbusinessFollow-Up StudiesAnnals of Oncology
researchProduct